FHA
BEAM icon

Flagship Harbor Advisors’s Beam Therapeutics BEAM Stock Holding History

Flagship Harbor Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80
Closed -$2.22K – 866
2025
Q4 		$2.22K Buy
+80
New +$2.04K ﹤0.01% 1832
2021
Q2 		– Sell
-3,590
Closed -$287K – 639
2021
Q1 		$287K Buy
3,590
+585
+19% +$55.7K 0.03% 488
2020
Q4 		$245K Buy
3,005
+155
+5% +$7.62K 0.03% 475
2020
Q3 		$70K Hold
2,850
– – 0.01% 753
2020
Q2 		$79K Hold
2,850
– – 0.01% 717
2020
Q1 		$51K Buy
+2,850
New +$61.9K 0.01% 745

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Flagship Harbor Advisors's BEAM Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 80 shares — an estimated $2.22K sold.

Flagship Harbor Advisors first reported a position in BEAM in Q1 2020 and held it in 6 quarters. The position peaked at $287K in Q1 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 80 Beam Therapeutics shares in Q1 2026, an estimated $2.22K.
  • Flagship Harbor Advisors first reported a position in Beam Therapeutics in Q1 2020 and held it in 6 quarters.
  • Flagship Harbor Advisors's Beam Therapeutics position peaked at $287K in Q1 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.